Summary The means by which oncogenes and their products activate malignant tranformation are currently under intense investigation. However, published papers on experiments using human tumour material do not always report in detail their methods of collection or storage of the specimens. In order to assess the stability of oncogene encoded proteins following collection or storage of human tumour biopsies, we have examined the rate of decay of the c-myc, neu and EGF-receptor proteins. Solid (Bradford, 1976) . Western blotting was performed essentially according to Towbin et al. (1979).
There is accumulating evidence that oncogenes, some of which encode proteins thought to be involved in normal cellular growth functions, play a role in malignant transformation. Alterations in sequence or expression of genes such as c-myc (Slamon et al., 1984) , ras (Lemoine, 1990 ) and c-erbB-2 (Gullick & Venter, 1989) are associated with several common solid human tumours. Abnormal expression of the EGF receptor has also been reported in squamous cell carcinomas of cervix, vulva, head and neck, oesophagus, glial cells, lung and breast.
Since neoplasia may result from the accumlation of multiple oncogenic events (Kahn & Graf, 1988) it is important to study the pattern of expression of oncogenes in human tumours. Such studies may identify consistent changes to particular oncogenes which may be useful in understanding the mechanisms of carcinogenesis, provide helpful prognostic information and indicate targets for new forms of therapy.
To date, the extent of expression and localisation of oncogene products have been routinely analysed in archival material of patients by semi-quantitative immunohistological staining. Various methods of fixation have been employed, and the lapse of time between collection and fixation has not generally been reported. Since immunohistochemical staining does not indicate the integrity of the oncoproteins, proteolysis which may have occurred during tumour processing may lead to diminished staining intensity and an underestimate of the degree of oncoprotein expression.
A more quantitative asasy for detecting the presence of a particular oncogene product which also determines its molecular weight, and therefore its integrity, is immunoblotting of tumour extracts. In this technique, fresh or frozen resected tumour tissue is required. We have examined the decay of some commonly measured oncogene products to establish their stability in human tumour biopsies stored under various conditions and for different time periods. The information obtained will ensure that future studies of oncoprotein estimation by immunostaining are unlikely to be invalidated by variable extents of oncoprotein loss.
Materials and methods

Cell lines
The cell lines A43 1, from a human vulval carcinoma (Stoscheck & Carpenter, 1983) , B104 1.1, NIH 3T3 cells transformed with the mutant neu oncogene (Schechter et al., 1984) and Colo 320 HSR, a human colonic apudoma derived cell line (Alitalo et al., 1983) (Bradford, 1976 In the case of the c-myc product, tumour segments were crushed to a powder while frozen and then scooped into a different lysis buffer containing 25 mM Tris/HCl, pH 8.0, 150 mM NaC 1, 1% aprotinin (Sigma), 0.5% soya bean trypsin inhibitor (Sigma), 3 mM PMSF and 1% SDS. The suspension was thoroughly homogenised by forcing it through a syringe and needle several times. Protease inhibitors were essential to prevent breakdown of the myc protein during homogenisation. The addition of 1% SDS was necessary to release all the c-myc proteins from the nucleus.
Densitometer scans on immunoblots made transparent with three-in-one lubricating oil (Maciewicz & Knight, 1988) were carried out to quantitate the extent of protein expression using a LKB Laser Ultrascan XL. 
Results
Using immunohistological staining, it has sometimes been observed that regional variations in oncoprotein expression occur in human and animal tumours. Since we wished to use segments of individual tumours to analyse oncoprotein breakdown we first determined whether expression varied between tumour slices. Consequently, Western blots were performed using cell extracts obtained from all the segments of one tumour homogenised immediately after resection. While there is slight variation in the intensity of the bands, there is, overall, equal regional distribution of each of the oncogene products in all the randomly cut sections of the tumour (Figures la, 2a and 3a) . We therefore went on to examine the stability of the oncogene products at various time intervals after resection.
The stability of each oncogene protein was determined by preparing extracts of similar sized tumour segments left for various times in PBS at room temperature. Figure lb and c show that the EGF receptor protein was still present afer 24h incubation, whether the time intervals were initiated directly after tumour removal or when the tumour was thawed out at room temperature after storage in liquid nitrogen. Densitometer scans, obtained from the blots of the EGF receptor protein (Figure ld) , showed some variation in the amounts present at each time point but that there was no progressive disappearance of the EGF receptor protein with time since the signal levels were within the limits of variation obtained with the control blot (Figure la) . Two EGFreceptor protein bands were observed in extracts of solid tumours of A431 cells (Figure la, lanes 1-8; Figure lc , lanes 1-7). It has been reported that the protease calpain is present in the cytoplasm of many mammalian cells and that in the presence of calcium, this will cleave detergent solubilised EGF receptors to a species which runs at 150,000 mol.wt (Cohen et al., 1982) . Despite including the calcium chelator EGTA in the tumour homogenisation buffer to inhibit this enzyme, two bands were generally obtained but with noticeably different intensities in extracts of different tumours and the lower band was sometimes absent. This doublet has also been observed in tumour extracts of a squamous cell carcinoma of the cervix (Gullick et al., 1986) .
The stability of the neu protein is shown in Figure 2b (Figure 2a) .
In intitial experiments using time periods up to 24 h, the c-myc protein was found to be relatively unstable since the signal obtained was drastically reduced in intensity after storage of the tumour segments for 2 h at room temperature. We therefore examined shorter time periods at more frequent intervals (Figure 3b and c) . It would appear from the densitometer scans (Figure 3d ) that the c-myc product is substantially degraded between 20 and 60 min after removal of the tumour. This pattern of decay was repeatedly obtained with tumours from different mice. As shown in Figure 3b (Figure 3a) shows equal distribution of c-myc protein throughout the tumour so the pattern of disappearance of the protein cannot be attributed to non-homogeneous expression of the oncogene product. There are other less intense bands recognised by the antibody apart from the p62000 band ( Figure  3a ). These could be non-specific binding of the antibody to proteins peculiar to growth of the tumour in nude mice since they have been observed to vary in quantity from mouse to mouse and are absent in some tumours and in the Colo 320 cell line extract (Figure 3a, lane 8) .
A different tumour was used for each of the gels in Figures  la-c, 2a-c and 3a -c. Reproducibility of results was obtained in at least three tumours from three different animals for each of the gels in Figures lb, c, 2b, c, 3a , b and c. For each of the control blots (Figures a and 2a) , the experiment was performed on two tumours from two different animals with similar results.
While the H-ras protein was detectable as a weak band in immunoblots prepared from cultured EJ6 cells, the amount of ras protein detected in the tumour tissue was lower, producing extremely faint bands in the immunoblots (data not shown). We could not, therefore, accurately determine the degradation rate of the H-ras protein. The stability of a particular oncoprotein in live cells does not necessarily predict its rate of degradation in dying tissue. The balance between protein synthesis and the natural rate of degradation will be altered in anoxic, moribund cells leading to a progressive reduction in intact protein levels at an unpredictable rate. Despite this we have found that the decay of oncogene products in resected tissue is not far different from their natural half-life. The EGF-receptor protein has a half life of 10 h (Stoscheck & Carpenter, 1984) and our studies show that the protein is still stable after 24 h. The neu protein, which has a half-life of about 7 h (Hudziak et al., 1989) , is also stable up to 24 h from our experiments.
The c-myc protein has a natural half-life of about 30 min (Ramsay et al., 1984) . In our experiments c-myc starts to decay between 20 min and 1 h, at which time it is no longer detectable on immunoblots. Although we cannot draw definite conclusions about the stability of the ras gene product, it would appear that it is still present after 24 h.
We have found that frozen tumour fragments left to thaw for 24 h in PBS displayed autolysis, although no autolysis was evident after 20 min. c-erbB-2 expression can still be detected by immunostaining in human fetuses 24 h postmortem despite obvious autolysis (P. Quirke, personal communication). Our Western blot results suggest that degradation of the c-myc protein begins after 20 min and by 1 h the c-myc product has been substantially degraded. Therefore, one could not confidently assay for c-myc expression after 20 min when resected tumour tissue still appears intact, whereas for c-erbB-2 and EGF-receptor, one could still detect the proteins even when resected tissue has undergone autolysis. In the light of these experiments, it would be worthwhile for future studies on oncogene expression in human tumours to follow standard procedures for tumour collection if useful interpretation is to be made of the data.
In addition, these results suggest that studies on the pattern of expression of the c-erbB-2 and EGF-receptor could be examined in metastatic disease. The mechanisms involved in metastasis are not known and may be similar to or different from those initiating transformation.
In the clinical situation where patients relapse some months or years after removal and treatment of the primary tumour, distant metastasis can occur at mulitple secondary sites throughout the body. In such instances, death usually results from failure to respond to drug therapy. Thus there is an urgent need to develop new forms of treatment for this group of patients. To elucidate the role of oncogenes in metastatic disease it will be necessary to employ autopsy material.
The EGF-receptor and neu proteins are good candidates for studying multiple metastases since they are stable for up to 24 h post-mortem. The c-myc protein has a very short biological life and could not be examined in such studies. The very limited stability of the c-myc protein also suggests that care should be taken in interpreting results from archival material whose provenance is not known.
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